# Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study

> **NCT06033833** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Sanofi** · enrollment: 335 (actual)

## Conditions studied

- Asthma

## Interventions

- **DRUG:** Amlitelimab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT06033833
- **Lead sponsor:** Sanofi
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-09-05
- **Primary completion:** 2029-06-25
- **Final completion:** 2029-06-25
- **Target enrollment:** 335 (ACTUAL)
- **Last updated:** 2025-09-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06033833

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06033833, "Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06033833. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*